DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: CYMBALTA

Summary for Tradename: CYMBALTA

Patents:3
Applicants:1
NDAs:1
Suppliers: see list17
2013 Sales:$5,219,860,000
drug
patent expirations by year for
 CYMBALTA

Clinical Trials for: CYMBALTA

The Cymbalta Pregnancy Registry
Status: Recruiting Condition: Pregnancy

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
Status: Completed Condition: Diabetic Neuropathy, Painful

A Study for the Treatment of Diabetic Peripheral Neuropathic Pain
Status: Completed Condition: Diabetic Neuropathies

Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury
Status: Terminated Condition: Traumatic Brain Injury; Depression

Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus
Status: Completed Condition: Systemic Lupus Erythematosus

A Study to Evaluate the Pharmacokinetics of Duloxetine in Chinese Han Healthy Subjects
Status: Completed Condition: Healthy

Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome
Status: Completed Condition: Anxiety Disorder

Cymbalta for Fibromyalgia Pain
Status: Recruiting Condition: Fibromyalgia

Duloxetine - Warfarin Pharmacodynamic Study
Status: Completed Condition: Anticoagulant Effect of Warfarin When Taken With Duloxetine.

Duloxetine for Chronic Depression: a Double-blind Study
Status: Active, not recruiting Condition: Dysthymic Disorder; Depressive Disorder NOS

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
CYMBALTA
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427Aug 3, 2004RXNo<disabled><disabled>
Lilly
CYMBALTA
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427Aug 3, 2004RXNo<disabled><disabled>
Lilly
CYMBALTA
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427Aug 3, 2004RXNo<disabled><disabled>
Lilly
CYMBALTA
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427Aug 3, 2004RXNo<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CYMBALTA

Drugname Dosage Strength RLD Submissiondate
duloxetine hydrochlorideDelayed-release Capsules40 mgCymbalta5/10/2012
duloxetine hydrochlorideDelayed-release Capsules20 mg, 30 mg and 60 mgCymbalta8/4/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc